2. Vitamin D Related/Nuclear Receptor Immunology/Inflammation NF-κB Metabolic Enzyme/Protease
  3. VD/VDR Aryl Hydrocarbon Receptor NF-κB Cytochrome P450
  4. 20-Hydroxyvitamin D3

20-Hydroxyvitamin D3  (Synonyms: 20(OH)D3; 20S-Hydroxyvitamin D3)

Cat. No.: HY-154825
COA
SDS
Handling Instructions Technical Support

20-Hydroxyvitamin D3 (20(OH)D3), a product of vitamin D3 hydroxylation, is a noncalcemic immunomodulator. 20-Hydroxyvitamin D3 binds to vitamin D receptor (VDR), activates VDR and aryl hydrocarbon receptor (AhR) signaling, stimulates CYP24A1 expression, and drives VDR nuclear translocation. 20-Hydroxyvitamin D3 inhibits NF-κB activity via IκBα upregulation. 20-Hydroxyvitamin D3 acts as a substrate for CYP27B1 and rat CYP24A1, undergoing hydroxylation to form dihydroxy-derivatives. 20-Hydroxyvitamin D3 inhibits cell proliferation, colony formation, migration, and tumor growth, and induces cell differentiation in cancer cells. 20-Hydroxyvitamin D3 can be used for the research of inflammatory and autoimmune diseases, melanoma, breast carcinomas, and hepatocarcinoma.

For research use only. We do not sell to patients.

20-Hydroxyvitamin D3

20-Hydroxyvitamin D3 Chemical Structure

CAS No. : 651734-12-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

20-Hydroxyvitamin D3 Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms
CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

20-Hydroxyvitamin D3 (20(OH)D3), a product of vitamin D3 hydroxylation, is a noncalcemic immunomodulator. 20-Hydroxyvitamin D3 binds to vitamin D receptor (VDR), activates VDR and aryl hydrocarbon receptor (AhR) signaling, stimulates CYP24A1 expression, and drives VDR nuclear translocation. 20-Hydroxyvitamin D3 inhibits NF-κB activity via IκBα upregulation. 20-Hydroxyvitamin D3 acts as a substrate for CYP27B1 and rat CYP24A1, undergoing hydroxylation to form dihydroxy-derivatives. 20-Hydroxyvitamin D3 inhibits cell proliferation, colony formation, migration, and tumor growth, and induces cell differentiation in cancer cells. 20-Hydroxyvitamin D3 can be used for the research of inflammatory and autoimmune diseases, melanoma, breast carcinomas, and hepatocarcinoma[1][2][3][4].

Cellular Effect
Cell Line Type Value Description References
HEK293 EC50
4.54 x 10-10 M
Compound: 20S(OH)D3
Antiproliferative activity against NHEK cells incubated for 24 hrs by [3H]thymidine incorporation assay
Antiproliferative activity against NHEK cells incubated for 24 hrs by [3H]thymidine incorporation assay
[PMID: 22404326]
In Vitro

20-Hydroxyvitamin D3 (20 min) acts as a substrate for mouse CYP27B1, with a 1α-hydroxylase activity of 0.135 mol product/min/mol CYP27B1[1].
20-Hydroxyvitamin D3 (0.1-100 nM; 24 h, 48 h) dose-dependently inhibits proliferation of human HaCaT keratinocytes and HDFn, with significant effects observed at concentrations ≥0.1 nM after 24 or 48 h of treatment[1].
20-Hydroxyvitamin D3 (0.1-100 nM; 8 h, 24 h) stimulates the expression of keratinocyte differentiation marker genes involucrin, CK10, and filaggrin in human HEKn after 8 or 24 h of treatment[1].
20-Hydroxyvitamin D3 (100 nM; 48 h) significantly increases protein levels of involucrin, CK10, CK14, and catalase, promoting differentiation of human HEKn[1].
20-Hydroxyvitamin D3 (1.5 h) induces VDR translocation to the nucleus in SKMEL-188 melanoma cells, with an EC50 of 0.19 μM[1].
20-Hydroxyvitamin D3 (23 h) acts as an agonist for AhR, stimulating AhR-dependent luciferase activity in reporter cells with an EC50 of 39 nM[1].
20-Hydroxyvitamin D3 (100 nM; 8 h) significantly upregulates the expression of VDR target gene CYP24A1 and AhR target genes CYP1A1 and CYP1B1 in human HEKn[1].
20-Hydroxyvitamin D3 (100 nM; 24 h) increases the proportion of a specific CD4 T cell subpopulation (downregulated CD4, increased CD69/ICOS) in activated human PBMC[1].
20-Hydroxyvitamin D3 (substrate-to-phospholipid ratios; 1 min kinetic assays, up to 30 min time course/product identification assays) is metabolized by rat CYP24A1 in phospholipid vesicles with a catalytic efficiency of 386 min−1 (mol substrate/mol phospholipid)−1, producing primarily 20,24-dihydroxyvitamin D3 and 20,25-dihydroxyvitamin D3 without generating secondary oxidized metabolites[2].
20-Hydroxyvitamin D3 (0.1-10 nM; 2 weeks, with fresh compound added every 72 h) significantly inhibits colony formation by SKMEL-188 melanoma cells in soft agar over a 2-week period[2].
20-Hydroxyvitamin D3 (0.1-100 nM; 7 d) inhibits proliferation of HepG2 hepatocellular carcinoma cells in a concentration-dependent manner, reducing CFU of colonies larger than 0.2 mm by 54% and colonies larger than 0.5 mm by 70% at 100 nM after 7 days of treatment[3].
20-Hydroxyvitamin D3 (10-100 nM; 14 d) inhibits proliferation of MDA-MB-453 human breast carcinoma cells in soft agar in a concentration-dependent manner, reducing CFU of colonies larger than 0.2 mm by 54% at 100 nM and inhibiting formation of colonies larger than 1.5 mm by 85% at 10 nM after 14 days of treatment[3].
20-Hydroxyvitamin D3 (100 nM; 26 d) inhibits proliferation of MCF7 human breast carcinoma cells in soft agar, reducing CFU of colonies larger than 0.2 mm by 78% at 100 nM after 26 days of treatment[3].
20-Hydroxyvitamin D3 (0.1 μM; 14 days, added every 72 h) significantly inhibits monolayer colony formation of SKMel-188 human melanoma cells[4].
20-Hydroxyvitamin D3 (1-100 nM; 12 days, added every 72 h) dose-dependently inhibits anchorage-independent colony formation of SKMel-188 human melanoma cells, with IC50 values ranging from 6.91 to 19.54 nM across colony size categories[4].
20-Hydroxyvitamin D3 (10-100 nM; 24 h) dose-dependently inhibits chemotactic migration of SKMel-188 human melanoma cells at both 10,000 and 100,000 cells/well densities[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

20-Hydroxyvitamin D3 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: human epidermal HaCaT keratinocytes, human dermal fibroblasts (HDFn)
Concentration: 0.1 nM, 1 nM, 10 nM,100 nM
Incubation Time: 24 h; 48 h
Result: Significantly inhibited proliferation of HaCaT keratinocytes.
Significantly inhibited proliferation of HDFn.

Real Time qPCR[1]

Cell Line: human neonatal epidermal keratinocytes (HEKn)
Concentration: 0.1 nM, 1 nM, 10 nM,100 nM
Incubation Time: 8 h; 24 h
Result: Significantly increased expression of involucrin, CK10, and filaggrin.
Significantly increased expression of involucrin, CK10, and filaggrin.

Immunofluorescence[1]

Cell Line: human neonatal epidermal keratinocytes (HEKn)
Concentration: 100 nM
Incubation Time: 48 h
Result: Significantly increased the percentage of fluorescence-positive cells for involucrin, CK10, CK14, and catalase.
Significantly increased mean fluorescence per cell for involucrin, CK10, CK14, and catalase.

Cell Proliferation Assay[3]

Cell Line: HepG2 hepatocellular carcinoma cells
Concentration: 0.1 nM, 10 nM, 100 nM
Incubation Time: 7 d
Result: Reduced the colony-forming units (CFU) of colonies larger than 0.2 mm by 54 ± 14% compared to vehicle control (100 nM).
Reduced CFU of colonies larger than 0.5 mm by 70 ± 20% compared to vehicle control (100 nM).
Did not significantly affect the total number of colonies larger than 0.2 mm (0.1 nM and 10 nM).
Greatly prevented the formation of colonies larger than 0.5 mm (0.1 nM and 10 nM).

Cell Proliferation Assay[4]

Cell Line: SKMel-188 human melanoma cells
Concentration: 100 nM
Incubation Time: 14 days (added every 72 h)
Result: Significantly reduced the number of colonies >0.2 mm compared to vehicle control.
In Vivo

20-Hydroxyvitamin D3 (5-30 μg/kg; i.p.; daily; 21 days) shows no detectable hypercalcemic effects, organ toxicity, or changes in clinical pathology markers in male C57BL/6 mice[3].
20-Hydroxyvitamin D3 (3 μg/kg; 7 days) exhibits no calcemic activity in rats[3].
20-Hydroxyvitamin D3 (3-30 μg/kg; i.p.) inhibits human melanoma tumor growth in immunocompromised NSG mice by 61% at a dose of 30 μg/kg (i.p., 5 days per week for 2 weeks) without visible toxicity, and improves animal health status relative to controls, while 3 μg/kg dose shows no significant effect[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (7-week-old female; vitamin D-deficient diet for 2 weeks prior to tumor implantation)[4]
Dosage: 30 μg/kg ; 3 μg/kg
Administration: i.p.; 5 days per week; 2 weeks
Result: Reduced accrued tumor volume by 61%.
Exhibited statistically significant tumor growth inhibition on days 13, 18, and 21 post-implantation via tumor volume or geometric mean of tumor dimensions.
Confirmed reduced tumor burden via bioluminescent imaging.
Showed no visible signs of toxicity.
Failed to produce a significant inhibitory effect on melanoma growth at 3 μg/kg dose.
Molecular Weight

400.64

Formula

C27H44O2
CAS No.
Appearance

Oil

Color

Colorless to light yellow

SMILES

C=C1CC[C@H](O)C/C1=C/C=C2[C@@](CC[C@]3([H])[C@@](C)(O)CCCC(C)C)([H])[C@]3(C)CCC/2
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

20-Hydroxyvitamin D3 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

20-Hydroxyvitamin D3651734-12-220(OH)D3 20S-Hydroxyvitamin D3VD/VDRAryl Hydrocarbon ReceptorNF-κBCytochrome P450Vitamin DVitamin D receptorAhRNuclear factor-κBNuclear factor-kappaBCYPsCYP27B1SKMEL-188 melanoma cellsMDA-MB-453 human breast carcinoma cellsvitamin D receptor (VDR)HepG2 hepatocellular carcinoma cellsIκBαHaCaT keratinocytesCYP24A1aryl hydrocarbon receptor (AhR)Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
20-Hydroxyvitamin D3
Cat. No.:
HY-154825
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.